Objective: To examine the possibility of using myoinositol as a marker of glucose intolerance to screen individuals for a 75-g oral glucose tolerance test (OGTT)
Methods: We measured urinary myoinositol enzymatically before and 2 h after a 75-g OGTT in 915 volunteers, who were classified according to the 1998 WHO criteria and divided into three groups based on fasting plasma glucose (FPG) levels which were as follows: 99 mg/dl; 100-125 mg/dl; and.126 mg/dl. Normal glucose tolerance (NGT) subjects with a 1 h plasma glucose ≥180 mg/dl were defined as preborderline (p-BD). We then compared Amyoinositol (ΔUMI: myoinositol/creatinine ratio 2 h after glucose loading - myoinositol/creatinine ratio before loading) in each group, with particular focus on the FPG 100-125 mg/dl group, to investigate relationships between glucose intolerance and ΔUMI.
Results: In the FPG 100-125 mg/dl group, using 10 mg/gCr as a tentative cut-off point for detecting glucose intolerance, ΔUMI was positive in 93% (37/40) of subjects with diabetes mellitus,68% (62/91) of subjects with impaired glucose tolerance,53% (25/47) of subjects with impaired fasting glucose,69% (18/26)of subjects who were p-BD, and 27% (37/137) of subjects with NGT.
Conclusions: These results show that ΔUMI can be used as a non-invasive, sensitive marker of glucose intolerance, and can be used to screen subjects for the 75-g OGTT as a secondary measure following FPG screening.
View full abstract